1M6MYTD1Y5YMAX
Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | March 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -69.14K | 53.90% |
| EBITDA | -51.78K | 1,785.35% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €220.09K |
Number of shares | 11.62M |
52-week high/low | €0.15 - €0.0189 |
| Dividends | No |
Beta | 0.30 |
P/E ratio | -0.15 |
PEG ratio | 0.00 |
P/B ratio | -0.08 |
P/S ratio | 0.00 |
Company profile
EGF Theramed Health Corp. stellt psychedelische Arzneimittel für die Behandlung der psychischen Gesundheit bereit. Das Unternehmen bietet Psychedelika zur Behandlung von Krankheiten wie behandlungsresistenten Depressionen, Angstzuständen, PTBS und Depressionen an. Das Unternehmen wurde im Jahr 2011 gegründet und hat seinen Hauptsitz in Vancouver, Kanada.
| Name | EGF Theramed Health Aktie |
| CEO | Connor Yuen |
| Headquarters | Vancouver,
bc Canada |
| Website | |
| IPO | 03/01/2017 |
| Employees | 2,500 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Pnk | EVAHF |
Cnq | TMED.CN |
Frankfurt | AUH.F |
München | AUH.MU |
Discover assets
Shareholders of EGF Theramed Health Aktie also invest in the following assets
